BioPharma

The global cell and gene therapy market has witnessed remarkable growth, with a market size of USD 15.46 billion in 2022. Projections indicate that by 2032, it could reach approximately USD 82.24 billion, showcasing a robust compound annual growth...

While the pharmaceutical industry has traditionally been seen as recession-proof, with a constant demand for medicines and new treatment options, it currently faces significant challenges. Economic uncertainty is on the rise, increasing the risks associated with early drug discovery,...

What is the Joint European HTA? Navigating pricing and reimbursement in the European Union (EU) can be a complex task for emerging biopharmaceutical companies (EBPs), defined as those with less than $200 million in estimated annual R&D spending or global...

In the biopharma industry, selecting the right contract development and manufacturing organization (CDMO) is pivotal to a successful pharmaceutical development journey. This decision hinges on two critical factors: a customer-centric approach and team cohesion. In this blog, we explore...

The biopharmaceutical sector is undergoing a significant transformation in treating complex diseases, especially in oncology, driven by innovative drug approaches. This shift entails personalized therapies, combination treatments, and novel go-to-market strategies to address specific patient groups. As the industry...

Speeding up biomanufacturing using automated Process Analytical Technology (PAT) systems A2P2 and Micro Sequential Injection (SI), two cutting-edge process analysers, have been cited as autonomous PAT platform that enables quick testing and release of biopharmaceutical products. An insight has showcased two...

Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with traditional medicine. These therapies involve introducing, replacing, or deactivating genes in cells, either inside or...